BACKGROUND: A comparison of the cost-effectiveness of becaplermin plus good wound care (BGWC) versus good wound care (GWC) alone in treating patients with diabetic foot ulcers (DFUs) may enable physicians and health-care decision makers in the United States to make better-informed choices about treating DFUs, which currently contribute to a substantial portion of the economic burden of diabetes. METHODS: Data from three phase III trials were used to predict expected 1-year costs and outcomes, including the average percentage reduction from baseline in wound surface area (WSA), the direct costs of DFU therapy, and the cost per cm(2) of WSA reduction. RESULTS: At 20 weeks, the BGWC group had a statistically greater probability of complete wound closure than the GWC group (50% versus 35%; P = .015). Based on reported WSA reduction rates, DFUs in the BGWC group were predicted to close by 100% at 27 weeks, and those in the GWC group were predicted to close by 88% at 52 weeks. The GWC group had higher total estimated 1-year direct cost of DFU care ($6,809 versus $4,414) and higher cost per cm(2) of wound closure ($3,501 versus $2,006). CONCLUSIONS: Becaplermin plus good wound care demonstrated economic dominance compared with GWC by providing better clinical outcomes via faster reduction in WSA and higher rates of closure at a lower direct cost.
BACKGROUND: A comparison of the cost-effectiveness of becaplermin plus good wound care (BGWC) versus good wound care (GWC) alone in treating patients with diabetic foot ulcers (DFUs) may enable physicians and health-care decision makers in the United States to make better-informed choices about treating DFUs, which currently contribute to a substantial portion of the economic burden of diabetes. METHODS: Data from three phase III trials were used to predict expected 1-year costs and outcomes, including the average percentage reduction from baseline in wound surface area (WSA), the direct costs of DFU therapy, and the cost per cm(2) of WSA reduction. RESULTS: At 20 weeks, the BGWC group had a statistically greater probability of complete wound closure than the GWC group (50% versus 35%; P = .015). Based on reported WSA reduction rates, DFUs in the BGWC group were predicted to close by 100% at 27 weeks, and those in the GWC group were predicted to close by 88% at 52 weeks. The GWC group had higher total estimated 1-year direct cost of DFU care ($6,809 versus $4,414) and higher cost per cm(2) of wound closure ($3,501 versus $2,006). CONCLUSIONS:Becaplermin plus good wound care demonstrated economic dominance compared with GWC by providing better clinical outcomes via faster reduction in WSA and higher rates of closure at a lower direct cost.
Authors: Maximillian A Weigelt; Hadar A Lev-Tov; Marjana Tomic-Canic; W David Lee; Ryan Williams; David Strasfeld; Robert S Kirsner; Ira M Herman Journal: Adv Wound Care (New Rochelle) Date: 2021-07-21 Impact factor: 4.730
Authors: James R Bardill; Melissa R Laughter; Michael Stager; Kenneth W Liechty; Melissa D Krebs; Carlos Zgheib Journal: Acta Biomater Date: 2021-10-30 Impact factor: 8.947
Authors: Jeffrey M Gimble; Trivia Frazier; Xiying Wu; Andrea Alarcon Uquillas; Claire Llamas; Theodore Brown; Doan Nguyen; H Alan Tucker; Douglas M Arm; Dale R Peterson; Bruce A Bunnell Journal: Plast Reconstr Surg Glob Open Date: 2018-11-21
Authors: Trivia Frazier; Andrea Alarcon; Xiying Wu; Omair A Mohiuddin; Jessica M Motherwell; Anders H Carlsson; Robert J Christy; Judson V Edwards; Robert T Mackin; Nicolette Prevost; Elena Gloster; Qiang Zhang; Guangdi Wang; Daniel J Hayes; Jeffrey M Gimble Journal: Biomolecules Date: 2020-09-27
Authors: Richard Hillson Bull; Karen Louise Staines; Agnes Juguilon Collarte; Duncan Shirreffs Bain; Nicola M Ivins; Keith Gordon Harding Journal: Int Wound J Date: 2021-08-10 Impact factor: 3.315